DBV Technologies (NASDAQ:DBVT) Stock Passes Above 50 Day Moving Average – Here’s What Happened

DBV Technologies S.A. (NASDAQ:DBVTGet Free Report)’s stock price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.54 and traded as high as $4.58. DBV Technologies shares last traded at $4.34, with a volume of 36,372 shares changing hands.

Wall Street Analyst Weigh In

Several research analysts have recently commented on DBVT shares. JMP Securities reissued a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a report on Friday, January 10th. StockNews.com assumed coverage on shares of DBV Technologies in a research note on Saturday. They issued a “hold” rating for the company. Finally, HC Wainwright raised their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th.

Check Out Our Latest Research Report on DBVT

DBV Technologies Trading Down 1.4 %

The stock has a market capitalization of $89.27 million, a PE ratio of -0.96 and a beta of 0.64. The business has a fifty day moving average price of $3.54 and a 200-day moving average price of $3.86.

DBV Technologies (NASDAQ:DBVTGet Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.90) by $1.10. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.17 million. On average, equities analysts anticipate that DBV Technologies S.A. will post -7.05 earnings per share for the current fiscal year.

About DBV Technologies

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.

See Also

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.